Bryan brings 15 years of legal experience and 20 years of medical experience, as both a legal counselor and medical practitioner. Prior to joining Tarsus, Bryan was a Partner at Knobbe Martens LLP, where he focused on intellectual property protection, infringement studies and due diligence for financings and strategic transactions, specifically with respect to pharmaceutical, biotechnology and medical device companies. Bryan counseled clients from the pre-Series A stage through exit, including Tarsus, which has been one of his clients since shortly after it was founded. In addition to his law practice, Bryan has practiced inpatient internal medicine since 2002, most recently as a per diem hospitalist with Kaiser Permanente, caring for patients both on hospital wards and in the ICU.
Prior to joining Knobbe Martens, Bryan entered medical school after one undergraduate year, and received his medical degree with honors from the University of Hawaii John A. Burns School of Medicine in 1999. He completed an internal medicine residency in the UCLA-affiliated Cedars-Sinai Medical Center program in Los Angeles in 2002, and is board certified in Internal Medicine. Bryan earned his law degree from the University of California, Berkeley School of Law in 2005. In law school, he received three American Jurisprudence Awards, two Prosser Awards and the Barbee Fellowship, researching conflicts of interest of hospital institutional review boards, and was also a summer extern for the Honorable Ronald T.Y. Moon, Chief Justice of the Hawaii Supreme Court.
What is Bryan Wahl's net worth?
The estimated net worth of Bryan Wahl is at least $4.23 million as of March 20th, 2025. Dr. Wahl owns 51,712 shares of Tarsus Pharmaceuticals stock worth more than $4,231,593 as of December 5th. This net worth estimate does not reflect any other assets that Dr. Wahl may own. Additionally, Dr. Wahl receives a salary of $619,090.00 as General Counsel at Tarsus Pharmaceuticals. Learn More about Bryan Wahl's net worth.
How old is Bryan Wahl?
Dr. Wahl is currently 46 years old. There are 3 older executives and no younger executives at Tarsus Pharmaceuticals. The oldest executive at Tarsus Pharmaceuticals is Mr. Jeffrey S. Farrow, CFO & Chief Strategy Officer, who is 62 years old. Learn More on Bryan Wahl's age.
What is Bryan Wahl's salary?
As the General Counsel of Tarsus Pharmaceuticals, Inc., Dr. Wahl earns $619,090.00 per year. There are 2 executives that earn more than Dr. Wahl. The highest earning executive at Tarsus Pharmaceuticals is Dr. Seshadri Neervannan Ph.D., Chief Operating Officer, who commands a salary of $759,200.00 per year. Learn More on Bryan Wahl's salary.
How do I contact Bryan Wahl?
Has Bryan Wahl been buying or selling shares of Tarsus Pharmaceuticals?
Bryan Wahl has not been actively trading shares of Tarsus Pharmaceuticals within the last three months. Most recently, Bryan Wahl sold 3,084 shares of the business's stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $50.11, for a transaction totalling $154,539.24. Following the completion of the sale, the general counsel now directly owns 51,712 shares of the company's stock, valued at $2,591,288.32. Learn More on Bryan Wahl's trading history.
Who are Tarsus Pharmaceuticals' active insiders?
Tarsus Pharmaceuticals' insider roster includes D. Ackermann (Director), Bobak Azamian (CEO), Andrew Goldberg (Director), Leonard Greenstein (CFO), Elizabeth Lin (Director), William Link, PhD (Director), Aziz Mottiwala (Insider), Seshadri Neervannan (COO), Bryan Wahl (General Counsel), and Dianne Whitfield (Chief Human Resources Officer). Learn More on Tarsus Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Tarsus Pharmaceuticals?
During the last year, insiders at the sold shares 10 times. They sold a total of 71,658 shares worth more than $3,759,005.28. The most recent insider tranaction occured on September, 24th when CEO Bobak R Azamian sold 6,000 shares worth more than $332,220.00. Insiders at Tarsus Pharmaceuticals own 9.0% of the company.
Learn More about insider trades at Tarsus Pharmaceuticals. Information on this page was last updated on 9/24/2025.
